Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
34
Frequently Asked Questions
What is Market Cap of Enlivex Ltd.?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Enlivex Ltd. market cap is $23.61M.
What is the 52-week high for Enlivex Ltd.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Enlivex Ltd. 52 week high is $27.15 as of August 31, 2026.
What is the 52-week low for Enlivex Ltd.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Enlivex Ltd. 52 week low is $1.35 as of August 31, 2026.
What is Enlivex Ltd. stock price today?
Enlivex Ltd. stock price today is $1.35.
What was Enlivex Ltd. stock price yesterday?
Enlivex Ltd. stock price yesterday was $1.48.
What is the Price-to-Book ratio of Enlivex Ltd.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Enlivex Ltd. P/B ratio is 0.011.
What is the 50-day moving average of Enlivex Ltd.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Enlivex Ltd. 50-day moving average is $4.43.